Biofil Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
BIOFILCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Biofil Chemicals reported FY2026 revenue of ₹2,839.52 Lakhs, down 15% from ₹3,340.22 Lakhs in FY2025. Net profit surged to ₹278.60 Lakhs from ₹55.78 Lakhs (a 5x increase), driven mainly by the disposal of a factory undertaking to Formo Plast Private Limited. EPS improved from ₹0.34 to ₹1.71. The company disclosed that factory renovation under revised Schedule M caused partial disruption in pharma operations, leading to the revenue decline. The Chemicals segment grew to ₹943.19 Lakhs from ₹674.18 Lakhs, while Pharma segment dropped sharply to ₹1,896.33 Lakhs from ₹2,666.04 Lakhs. The auditor issued an unmodified (clean) opinion with no qualifications.
The sharp profit growth is largely due to a one-time asset sale, not core operations. The negative operating cash flow of ₹60.49 Lakhs despite net profit of ₹278.60 Lakhs signals poor cash conversion quality. The revenue decline in the pharma segment due to factory disruption is a near-term operational concern.